... A web-based Atlas of Patient-Derived Xenografts of cancer patients:A resource of MURAL PDX data
Download csv Download xlsx
PDX ID Sample Site Sample Source Age Sample Collected PSA at diagnosis (ng/mL) Id Sample ID Current PDX Generation Average PDX Generation Time (days ± SEM) Tumor preparation2 Pubmed ID Created Date Audit Date Patient Id Gleason Score Primary Gleason Score Secondary Gleason Score Grade Group Tumour Grade D'Amico Risk Classification Primary Tumour Volume (cc) Treatment Prior to Specimen Collection PDX Host Type PDX Graft Site
305R Prostate Radical prostatectomy 75 2 14 305R 26 46 ± 2 Tumor solid 34413304 01/05/2022 11 a.m. 13/05/2024 1 a.m. 305 9 5 4 5 pT3bN1 7 73.4 None Testosterone supplemented Subcutaneous
305R Cx Prostate Radical prostatectomy 75 2 15 305R 45 (22*) 41 ± 1 Tumor solid 34413304 01/05/2022 11 a.m. 13/05/2024 1 a.m. 305 9 5 4 5 pT3bN1 7 73.4 None Castrate Subcutaneous
365R Prostate Radical prostatectomy 63 6.3 16 365R 8 224 ± 25 Tumor solid 34413304 01/05/2022 11 a.m. 13/05/2024 1 a.m. 365 9 4 5 5 pT3aN1 7 8.6 None Testosterone supplemented Renal
369R Prostate Radical prostatectomy 63 5.8 17 369R 9 105 ± 9 Tumor solid 34413304 01/05/2022 11 a.m. 13/05/2024 1 a.m. 369 9 4 5 5 pT3bN0 7 13.1 None Testosterone supplemented Subcutaneous
386R Prostate Radical prostatectomy 71 6.98 18 386R 12 135 ± 10 Tumor solid 34413304 01/05/2022 11 a.m. 13/05/2024 1 a.m. 386 9 4 5 5 pT3bN1 7 36.0 None Testosterone supplemented Renal
167.1R Prostate Radical prostatectomy 56 5.2 19 167.1R 19 121 ± 13 Tumor solid 34413304; 33620092 01/05/2022 11 a.m. 13/05/2024 1 a.m. 167 9 4 5 5 pT3bN0 7 34.6 None Testosterone supplemented Subcutaneous
167.2M Spine Surgery 59 5.2 20 167.2M 27 48 ± 2 Tumor solid 34413304; 33620092 01/05/2022 11 a.m. 13/05/2024 1 a.m. 167 9 4 5 0.0 ADT, docetaxel Testosterone supplemented Subcutaneous
167.2M Cx Spine Surgery 59 5.2 21 167.2M 29 (12*) 94 ± 7 Tumor solid 34413304; 33620092 01/05/2022 11 a.m. 13/05/2024 1 a.m. 167 9 4 5 0.0 ADT, docetaxel Castrate Subcutaneous